Gas6 Helps Calcification Spread Across the Aortic Valve

discover how gas6 may promote the spread of calcification across the aortic valve, offering new insight into valve disease progression.

Aortic valves can harden from the inside out, as tiny mineral deposits spread into neighboring tissue. The process turns flexible tissue into something more bone-like—and can gradually narrow the heart’s exit passage. Researchers are now tracing how aging cells may help those deposits travel.
Calcification appears in several tissues as we age, but its presence in blood vessels and the heart is especially concerning. In calcific aortic valve disease, or CAVD, pockets of calcium can expand beyond their starting points, damaging the valve’s structure and making it harder for blood to flow. Treatments that reliably reverse established tissue calcification remain elusive. Approaches such as EDTA chelation have shown limited effects, while vitamin K supplementation may slow calcification for some people, with benefits that vary. A new study investigates how signals from aging valve cells might encourage nearby cells to join the process.

The study focused on valvular interstitial cells, the cells that help maintain the structure of the aortic valve. Under conditions that favor calcification, these cells can take on features associated with bone-forming cells. The researchers found that calcifying cells released unusually large numbers of mitochondrial-derived vesicles (MDVs). When neighboring cells took up these vesicles, they became more prone to calcify, suggesting that MDVs may help carry the process from one part of the valve to another.

To investigate how the vesicles form, the team used human valve tissue, cell experiments, molecular profiling, and animal studies. High-resolution imaging revealed that, under pro-osteogenic conditions, mitochondria could reshape into ring-like, or “donut-shaped,” structures. These structures provided a physical platform for MDVs to bud from the mitochondria.

The researchers also found signs of cellular senescence in diseased valve tissue and in cells exposed to calcification-promoting conditions. Senescent cells release signaling molecules, sometimes called senokines, that can influence nearby cells. Among the candidate signals identified in the study was Gas6, a protein secreted by senescent cells.

Gas6 did not appear to create the ring-shaped mitochondrial structures. Instead, experiments suggested it helped complete the final step in releasing MDVs, known as terminal scission. The proposed chain of events begins with a rise in intracellular calcium, followed by activation of CaMKII and phosphorylation of DRP1, proteins involved in mitochondrial dynamics. Together, these changes supported the final separation of vesicles from their mitochondrial source.

Blocking CaMKII or DRP1 reduced MDV release and lowered calcification in recipient cells. In animals, deleting Gas6 was associated with less valve narrowing, calcification, and fibrotic remodeling. These findings point to Gas6 as a possible upstream control point in the process, rather than simply another marker of diseased tissue.

Directly targeting CaMKII or DRP1 could carry wider risks. DRP1 supports normal mitochondrial division, recycling, and quality control, while CaMKII has roles in heart contraction, brain signaling, and immune activity. Interfering with either protein throughout the body could disrupt functions beyond the valve. Because Gas6 sits upstream of both proteins and is secreted by cells, the researchers suggest that strategies aimed at Gas6 merit further investigation as a way to limit calcification’s spread.

discover how gas6 may promote the spread of calcification across the aortic valve and what this process could mean for valve disease.

How Gas6 may help calcification spread across the aortic valve

Calcific aortic valve disease often begins in small, localized deposits. Over time, however, mineralization can extend into nearby valve tissue, stiffening the leaflets that open and close with every heartbeat. As the valve becomes less flexible, blood has a harder time passing from the heart into the aorta. A new study points to a possible messenger in this outward spread: Gas6, a protein released by aging, or senescent, cells.

The finding offers a closer look at how calcification may travel between cells rather than simply accumulate in one place. Researchers found that Gas6 can encourage valvular cells to release tiny, mitochondria-derived packages that promote calcifying behavior in neighboring cells. In other words, an aging cell may influence the local environment in ways that help nearby cells follow the same harmful path.

This is a significant biological clue, but not a ready-made treatment. The work helps explain a potential mechanism in aortic valve calcification; it does not show that a Gas6-targeting therapy can reverse established deposits or safely prevent disease in people. Understanding that distinction helps put the discovery in perspective: it identifies a possible point of intervention while also revealing why tackling calcification remains challenging.

“The study’s central idea is that senescent valve cells may do more than age in place: through Gas6 and mitochondrial-derived vesicles, they may help send calcification-promoting signals to their neighbors.”

Why does calcification spread through the aortic valve?

The aortic valve is made up of active living tissue, not an inert flap. Its cells respond to mechanical stress and signals in their surroundings. With age and disease, some of these cells can acquire features associated with bone-building cells. They begin to support the deposition of calcium-containing material in tissue where it does not belong. As deposits develop and the valve stiffens, the disease can affect the valve’s structure and ability to open fully.

That process is more complicated than calcium simply settling onto the valve. Cells help shape the local environment, and signals released by one cell may alter the behavior of another. This offers one way to understand why calcification can expand from an initial focus into adjacent tissue. The new research examined whether mitochondrial-derived vesicles—small packages released from mitochondria—could carry pro-calcific effects between human valvular interstitial cells, or hVICs.

In experiments, vesicles released by cells under calcification-promoting conditions encouraged recipient valve cells to adopt calcifying behavior. This suggests a potential chain of influence: stressed or aging cells release vesicles; neighboring cells receive them; and the local tissue becomes more permissive to mineralization. The study also observed features of cellular senescence in diseased human valve tissue and in hVICs exposed to pro-osteogenic conditions. Senescent cells can produce signaling molecules, sometimes called senokines, that affect nearby cells.

These findings help explain how disease may extend beyond its first visible deposits. They do not establish that vesicles are the only route by which calcification spreads. Valve disease involves multiple interacting processes, and mechanical forces, inflammation, cell state, and other molecular signals may also contribute. The research instead identifies one pathway that could be part of the wider picture of calcific aortic valve disease.

What role does Gas6 play in mitochondrial-derived vesicle release?

To investigate how senescent cells might influence their neighbors, the researchers combined several approaches, including analysis of human aortic valve tissue, molecular profiling, live imaging of individual cellular structures, and vesicle-transfer experiments. Their search identified growth arrest-specific 6 (Gas6) among a group of molecular candidates that were consistently increased across the profiling work. Gas6 is described here as a senokine: a signal associated with senescent cells that can affect surrounding tissue.

High-resolution imaging provided another piece of the puzzle. Under conditions that encouraged cells to calcify, mitochondria sometimes remodeled into ring-like, or donut-shaped, structures. These shapes appeared to serve as physical platforms for the budding of mitochondrial-derived vesicles. Gas6 did not seem to be required for the formation of these mitochondrial precursors. Instead, the results indicate that it helped promote a later step: terminal scission, when a budding vesicle is finally separated from its parent structure.

That distinction matters. The evidence suggests Gas6 is not simply switching vesicle production on from the beginning; it appears to support the final release of vesicles that can carry pro-calcific effects. When the team altered Gas6 signaling, vesicle release and the downstream calcification response changed, supporting a functional role for the signal rather than a mere association.

Still, a biological pathway observed in cell and tissue experiments does not automatically translate into a clinical treatment. The results bring together observations from human disease tissue and experimental models, but they do not show that blocking Gas6 in patients will slow valve narrowing or improve health outcomes. They do, however, make Gas6 a credible candidate for further investigation as an upstream regulator of valve calcification.

How do calcium, CaMKII, and DRP1 fit into the pathway?

The study traces Gas6’s effect through a sequence of events inside the cell. Gas6 was associated with increased intracellular calcium, followed by activation of calcium/calmodulin-dependent protein kinase II (CaMKII). CaMKII activity, in turn, supported phosphorylation of dynamin-related protein 1 (DRP1), a protein involved in mitochondrial dynamics. Together, the findings point to a calcium–CaMKII–DRP1 pathway that helps the final separation of mitochondrial-derived vesicles.

Put simply, the proposed mechanism connects an external signal from senescent cells with an internal process that controls the release of vesicles. Gas6 appears to encourage a cell’s calcium signaling; CaMKII responds to that change; and DRP1 helps carry out the final mechanical step in vesicle release. The released packages can then influence recipient cells and promote calcification-related behavior.

Researchers also tested whether interrupting parts of this chain would change the outcome. Pharmacological inhibition of CaMKII or DRP1 reduced the excessive release of vesicles and lowered subsequent calcification in recipient cells. These experiments support the pathway’s involvement, but they do not make either protein an obvious drug target for people with valve disease.

Both proteins have essential jobs beyond this particular process. DRP1 contributes to normal mitochondrial division, the removal of damaged mitochondria, and cellular quality control. Broadly suppressing it could interfere with these functions. CaMKII is involved in cardiac contraction, neuronal plasticity, and immune signaling. A drug that blocks its activity throughout the body might affect processes that healthy organs rely on. The pathway therefore reveals both an opportunity and a therapeutic dilemma: the closer researchers get to the mechanism, the more carefully they must distinguish harmful signaling from normal physiology.

Could targeting Gas6 lead to a treatment for valve calcification?

In an in vivo model, deleting Gas6 reduced several signs of disease, including aortic valve stenosis, calcification, and fibrotic remodeling. This result strengthens the case for studying Gas6, since it moves beyond isolated cell experiments and suggests that the signal can influence disease features in a living system. Because Gas6 sits upstream of CaMKII and DRP1, targeting it might offer a way to reduce the harmful vesicle pathway without directly blocking proteins that have many vital functions.

That possibility remains a research direction, not a treatment recommendation. The reported findings do not establish the safety, effectiveness, or appropriate delivery of a Gas6-directed therapy in people. Nor do they show that reducing new pro-calcific signals would remove mineral already deposited in the valve. Prevention of further progression and reversal of existing calcification are different goals, and the study mainly offers insight into a mechanism that could potentially be slowed.

The broader treatment landscape reinforces the need for caution. There are no established therapies that reliably undo calcification in tissues. Approaches such as chelation have not shown large effects, while evidence that vitamin K supplementation may slow calcification remains variable and does not guarantee an individual benefit. These broader observations are not a reason to start or stop a supplement or medication without clinical advice. Anyone with concerns about valve disease should discuss symptoms, imaging findings, and risk management with a qualified health professional.

For researchers, the next steps include testing how Gas6 behaves across different stages of human disease, determining whether its effects can be selectively modified, and examining whether changes in vesicle release predict meaningful changes in valve function. The key question is whether an intervention can reduce harmful signaling without disturbing the normal work of mitochondria, heart muscle, and other tissues. That balance will shape whether Gas6-targeted strategies can move from a promising mechanism toward a practical approach for limiting calcification spread.

Share this post :

Partager cet article :

Facebook
Twitter
LinkedIn
Pinterest
Picture of Gabrielle
Hello, I'm Gabrielle, a 36-year-old writer passionate about health, wellness, and longevity. With a focus on providing insightful and practical content, I aim to empower individuals to lead healthier and more fulfilling lives. Join me on this journey to explore the best practices for well-being and longevity.

Create a new perspective on life

Your Ads Here (365 x 270 area)
Latest News
Derniers articles
Top categories
Top catégories

Create a new perspective on life

Your Ads Here (365 x 270 area)

Subscribe our newsletter

Don’t miss out on the latest insights, tips, and breakthroughs in longevity, wellness, and cutting-edge health technologies! Subscribe to our newsletter and get expert content directly in your inbox. Stay informed about new trends, exclusive articles, and the latest discoveries that can help you live a longer, healthier life. Join our community of like-minded individuals and start your journey today!

Abonnez-vous à la newsletter

Ne manquez pas les dernières informations, conseils et avancées en matière de longévité, de bien-être et de technologies de pointe dans le domaine de la santé ! Abonnez-vous à notre lettre d’information et recevez des informations d’experts directement dans votre boîte de réception. Restez informé des nouvelles tendances, des articles exclusifs et des dernières découvertes qui peuvent vous aider à vivre plus longtemps et en meilleure santé. Rejoignez notre communauté de personnes partageant les mêmes idées et commencez votre voyage dès aujourd’hui !